Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Oct;46(10):1283-95.
doi: 10.1038/bmt.2011.35. Epub 2011 Mar 28.

Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD

G C Hildebrandt  1 , T Fazekas, A Lawitschka, H Bertz, H Greinix, J Halter, S Z Pavletic, E Holler, D Wolff
Affiliations
Review

Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD

G C Hildebrandt et al. Bone Marrow Transplant. 2011 Oct.

Abstract

This consensus statement established under the auspices of the German working group on BM and blood stem cell transplantation (DAG-KBT), the German Society of Hematology and Oncology (DGHO), the Austrian Stem Cell Transplant Working Group, the Swiss Blood Stem Cell Transplantation Group (SBST) and the German-Austrian Pediatric Working Group on SCT (Päd-Ag-KBT) summarizes current evidence for diagnosis, immunosuppressive and supportive therapy to provide practical guidelines for the care and treatment of patients with pulmonary manifestations of chronic GVHD (cGVHD). Pulmonary cGVHD can present with obstructive and/or restrictive changes. Disease severity ranges from subclinical pulmonary function test (PFT) impairment to respiratory insufficiency with bronchiolitis obliterans being the only pulmonary complication currently considered diagnostic of cGVHD. Early diagnosis may improve clinical outcome, and regular post-transplant follow-up PFTs are recommended. Diagnostic work-up includes high-resolution computed tomography, bronchoalveolar lavage and histology. Topical treatment is based on inhalative steroids plus beta-agonists. Early addition of azithromycin is suggested. Systemic first-line treatment consists of corticosteroids plus, if any, continuation of other immunosuppressive therapy. Second-line therapy and beyond includes extracorporeal photopheresis, mammalian target of rapamycin inhibitors, mycophenolate, etanercept, imatinib and TLI, but efficacy is limited. Clinical trials are urgently needed to improve understanding and treatment of this deleterious complication.

PubMed Disclaimer

Conflict of interest statement

Hildegard Greinix served as member of a steering committee for a chronic GVHD study of Therakos and received honoraria from Therakos for research presentations in corporate symposia at international scientific meetings. The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Diagnostic and clinical care work-up algorithm for lung injury following allo-SCT. (1) Routine PFT screening is recommended 3, 6, 9, 12, 18 and 24 months after allo-SCT and then once per year. (2)Impaired PFT should be at least a drop in FEV1 >5% over the last 12 months or a LFS ⩾2 or a FEV1 <80% (GOLD I) with FEV1/FVC >0.7. (3) The decision, whether a transbronchial or an open lung biopsy may be performed, has to be made carefully on a case by case basis in the context of radiographical findings, the risk of potential complications and the expected clinical consequences to be made depending upon biopsy results.
Figure 2
Figure 2
Therapeutic algorithm for lung injury following allo-SCT. TKI=tyrosine kinase inhibitor.
See this image and copyright information in PMC

Comment in

References

    1. Abou-Mourad YR, Lau BC, Barnett MJ, Forrest DL, Hogge DE, Nantel SH. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplant. 2010;45:295–302. doi: 10.1038/bmt.2009.128. - DOI - PubMed
    1. Bhatia S, Francisco L, Carter A, Sun CL, Baker KS, Gurney JG. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007;110:3784–3792. doi: 10.1182/blood-2007-03-082933. - DOI - PMC - PubMed
    1. Schmitz N, Eapen M, Horowitz MM, Zhang MJ, Klein JP, Rizzo JD. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the international bone marrow transplant registry and the European group for blood and marrow transplantation. Blood. 2006;108:4288–4290. doi: 10.1182/blood-2006-05-024042. - DOI - PMC - PubMed
    1. Chiodi S, Spinelli S, Ravera G, Petti AR, Van Lint MT, Lamparelli T. Quality of life in 244 recipients of allogeneic bone marrow transplantation. Br J Haematol. 2000;110:614–619. doi: 10.1046/j.1365-2141.2000.02053.x. - DOI - PubMed
    1. Fraser CJ, Bhatia S, Ness K, Carter A, Francisco L, Arora M. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood. 2006;108:2867–2873. doi: 10.1182/blood-2006-02-003954. - DOI - PMC - PubMed

Publication types